Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
With a standard mobilization regimen using G-CSF, approximately 5% of allogeneic donors does
not mobilize enough CD34+ cells to reach an optimal dose for transplantation and are
therefore called "poor mobilizers". A generally accepted optimum CD34+ PBSC dose for
allogeneic transplantation is > 4.5 x 106/kg body weight of the recipient. The minimum total
CD34+ PBSC dose certainly amounts to 2 x 106/kg body weight of the recipient.The objective of
this trial is to assess the efficacy of a single dose of Plerixafor as salvage procedure in
allogeneic stem cell donors with a poor CD34+ cell yield after the first day of peripheral
blood stem cell collection.
Phase:
Phase 2
Details
Lead Sponsor:
Technische Universität Dresden
Collaborators:
Cellex Gesellschaft für Zellgewinnung mbH Dresden Cellex Gesellschaft für Zellgewinnung mbH Köln University Hospital Carl Gustav Carus